Serving To Educate Primary Care Clinicians On Metabolic Issues
Evidence Based Medicine Header 1
Medical Education Header 2
Peer-to-peer Exchange Header 3
Metabolic Diseases Header 4
News: Prescriber's Letter December 2014

Trulicity (TRUE-lih-sih-tee, dulaglutide) is another GLP-1 agonist for type 2 diabetes...after Byetta, Bydureon, Tanzeum, and Victoza.

These injectables will become more popular because they can lead to weight loss...and they rarely cause hypoglycemia.

Consider them a possible add-on to metformin...along with gliptins, glitazones, sulfonylureas, insulin, etc.

Use this table for “ballpark” comparisons...and dosing frequency.


GLP-1 Agonist

~ A1C Decrease

~ Weight Loss

~ Cost/month

Dosing Frequency

albiglutide (Tanzeum)

1 %

2 lbs



exenatide (Byetta)

1 %

4 lbs



exenatide ER (Bydureon)

1.5 %

6 lbs



dulaglutide (Trulicity)

1.5 %

6 lbs



liraglutide (Victoza)

1.5 %

6 lbs




Also consider the ease of use of the different pen devices.

Bydureon and Tanzeum are likely the trickiest.  These require reconstitution by the patient or caregiver.  The others don’t need mixing.


For the most recent full article AND to access all of the benefits of Prescriber's Letter subscribe to an option below:

Prescriber's Letter offers PCMG Members a 10% discount at two subscription levels:

The Gold Subscription is $129 and includes CME

The Platinum Subscription is $189 and provides enhanced CME and Live Webinar access 

Enter Discount Code PCMG15 when ordering either subscription HERE